Beta Bionics vs Neuronetics
Neuronetics is the larger business, with $149m of revenue in fiscal 2025 against $100m for Beta Bionics (1.5 times as much). Neuronetics grew faster (99.2% against 53.9%). Neuronetics kept more of each dollar of sales as profit: a net margin of -26.1% against -73.0%. Beta Bionics carries less debt relative to equity (0.0% against 312.8%).
| Latest fiscal year | Beta BionicsBBNX, 2025 | NeuroneticsSTIM, 2025 |
|---|---|---|
| Revenue | $100m | $149m |
| Revenue growth | 53.9% | 99.2% |
| Net income | −$73.2m | −$39.0m |
| Operating margin | -71.5% | -21.1% |
| Net margin | -73.0% | -26.1% |
| Return on equity | — | -155.7% |
| Free cash flow | −$56.2m | −$21.2m |
| Cash | $31.6m | $28.1m |
| Total debt | $0 | $70.0m |
| Debt to equity | 0.0% | 312.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 420 | 658 |
| Market value | $817m | $171m |
| Price vs our value range | — | — |
| Moat score | — | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 52 sales | 15 buys, 11 sales |